Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
L Malcovati, E Hellström-Lindberg… - Blood, The Journal …, 2013 - ashpublications.org
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …
an Expert Panel was selected according to the framework elements of the National Institutes …
[PDF][PDF] Myelodysplastic syndromes: recent advances
EP Alessandrino, S Amadori, M Cazzola… - …, 2001 - haematologica.org
1Department of Hematology, University of Pavia School of Medicine, IRCCS Policlinico S.
Matteo, Pavia; 2Dept. of Hematology, University Tor Vergata, Rome; 3Division of …
Matteo, Pavia; 2Dept. of Hematology, University Tor Vergata, Rome; 3Division of …
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
A Raza, P Meyer, D Dutt, F Zorat, L Lisak… - Blood, The Journal …, 2001 - ashpublications.org
Thalidomide was administered to 83 patients with myelodysplastic syndrome (MDS), starting
at 100 mg by mouth daily and increasing to 400 mg as tolerated. Thirty-two patients stopped …
at 100 mg by mouth daily and increasing to 400 mg as tolerated. Thirty-two patients stopped …
Therapy related leukemias: susceptibility, prevention and treatment
Acute leukemia is the most frequent therapy-related malignancy. Together with the
increasing use of chemo-and radiotherapy, individual predisposing factors play a key role …
increasing use of chemo-and radiotherapy, individual predisposing factors play a key role …
The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes
U Platzbecker, LC Hofbauer, G Ehninger, K Hölig - Leukemia research, 2012 - Elsevier
Most patients with myelodysplastic syndromes (MDS) require transfusions due to chronic
anemia. Apart from the acute risks associated with transfusions, chronic anemia and red …
anemia. Apart from the acute risks associated with transfusions, chronic anemia and red …
The potential of amifostine: from cytoprotectant to therapeutic agent
V Santini, FJ Giles - Haematologica, 1999 - haematologica.org
BACKGROUND AND OBJECTIVE: Amifostine is an inorganic thiophosphate cytoprotective
agent known chemically as ethanethiol, 2-[(3-aminopropyl) amino] dihydrogen phosphate. It …
agent known chemically as ethanethiol, 2-[(3-aminopropyl) amino] dihydrogen phosphate. It …
Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients
E Terpos, A Mougiou, A Kouraklis… - British journal of …, 2002 - Wiley Online Library
Treatment with recombinant human erythropoietin (rHuEpo) improves anaemia in
approximately 20% of patients with myelodysplastic syndromes (MDS). We investigated the …
approximately 20% of patients with myelodysplastic syndromes (MDS). We investigated the …
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype
GM Rigolin, R Bigoni, R Milani, F Cavazzini… - Leukemia, 2001 - nature.com
At diagnosis, approximately half of myelodysplastic (MDS) patients presents a normal
karyotype by conventional cytogenetic analysis (CCA). Fluorescent in situhybridization …
karyotype by conventional cytogenetic analysis (CCA). Fluorescent in situhybridization …
Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a …
E Balleari, E Rossi, M Clavio, A Congiu, M Gobbi… - Annals of …, 2006 - Springer
Haemopoietic growth factors (HGF), ie erythropoietin [recombinant human erythropoietin
(rHEPO)] or granulocyte colony stimulating factor (G-CSF), alone or in combination, have …
(rHEPO)] or granulocyte colony stimulating factor (G-CSF), alone or in combination, have …
Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life
L Balducci - Cancer, 2006 - Wiley Online Library
Anemia is the most common cytopenia associated with myelodysplastic syndromes (MDS).
Current management relies on frequent red blood cell (RBC) transfusions and erythroid …
Current management relies on frequent red blood cell (RBC) transfusions and erythroid …